Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Pratibha Auti, Satish Gabhe & Kakasaheb Mahadik. (2019) Bioanalytical method development and its application to pharmacokinetics studies on Simvastatin in the presence of piperine and two of its synthetic derivatives. Drug Development and Industrial Pharmacy 45:4, pages 664-668.
Read now
Read now
Atcharaporn Limprasertkul, Nadine M Fisher, Atif B Awad & David R Pendergast. (2012) Statin Therapy Depresses Fat Metabolism in Older Individuals. Journal of the American College of Nutrition 31:1, pages 32-38.
Read now
Read now
Articles from other publishers (40)
Laura Alvarez-Jimenez, Felix Morales-Palomo, Alfonso Moreno-Cabañas, Juan F Ortega & Ricardo Mora-Rodriguez. (2023) Effects of Statins on Fat Oxidation Improvements After Aerobic Exercise Training. The Journal of Clinical Endocrinology & Metabolism 108:5, pages e139-e147.
Crossref
Crossref
Alyson Deprez, Zakaria Orfi, Lupann Rieger & Nicolas Alexandre Dumont. (2023) Impaired muscle stem cell function and abnormal myogenesis in acquired myopathies. Bioscience Reports 43:1.
Crossref
Crossref
HardeepNarendra Kumar Pandey, Sachin Kumar Singh, Bimlesh KumarLeander CorrieUmesh GoutamDileep Singh Baghel. (2022) Development and Validation of Reverse-Phase High-Performance Liquid Chromatography Based Bioanalytical Method for Estimation of Simvastatin in Rat's Plasma. ASSAY and Drug Development Technologies 20:8, pages 349-358.
Crossref
Crossref
Pierandrea Vinci, Emiliano Panizon, Letizia Maria Tosoni, Carla Cerrato, Federica Pellicori, Filippo Mearelli, Chiara Biasinutto, Nicola Fiotti, Filippo Giorgio Di Girolamo & Gianni Biolo. (2021) Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. International Journal of Molecular Sciences 22:21, pages 11687.
Crossref
Crossref
Spyridon Methenitis, Ioanna Stergiou, Smaragdi Antonopoulou & Tzortzis Nomikos. (2021) Can Exercise-Induced Muscle Damage Be a Good Model for the Investigation of the Anti-Inflammatory Properties of Diet in Humans?. Biomedicines 9:1, pages 36.
Crossref
Crossref
Yasin Ahmadi, Neda Mahmoudi, Bahman Yousefi & Ansar Karimian. (2020) The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; New functions for statins. Pharmacological Research 152, pages 104621.
Crossref
Crossref
Joseph Vamecq, Bérengère Papegay, Vincent Nuyens, Jean Boogaerts, Oberdan Leo & Véronique Kruys. (2020) Mitochondrial dysfunction, AMPK activation and peroxisomal metabolism: A coherent scenario for non-canonical 3-methylglutaconic acidurias. Biochimie 168, pages 53-82.
Crossref
Crossref
João Ettinger, Paulo Vicente Filho, Euler Ázaro & Paulo Benigno. 2020. Gastric Bypass. Gastric Bypass
255
263
.
Juan M. Suárez-Rivero, Carmen J. Pastor-Maldonado, Mario de la Mata, Marina Villanueva-Paz, Suleva Povea-Cabello, Mónica Álvarez-Córdoba, Irene Villalón-García, Alejandra Suárez-Carrillo, Marta Talaverón-Rey, Manuel Munuera & José A. Sánchez-Alcázar. (2019) Atherosclerosis and Coenzyme Q10. International Journal of Molecular Sciences 20:20, pages 5195.
Crossref
Crossref
Ramesh C. Gupta, Robin B. Doss, Wolf-D. Dettbarn & Dejan Milatovic. 2019. Biomarkers in Toxicology. Biomarkers in Toxicology
355
373
.
Hyunbeom Lee, Jong Min Choi, Joo-Youn Cho, Tae-Eun Kim, Hwa Jeong Lee & Byung Hwa Jung. (2018) Regulation of endogenic metabolites by rosuvastatin in hyperlipidemia patients: An integration of metabolomics and lipidomics. Chemistry and Physics of Lipids 214, pages 69-83.
Crossref
Crossref
Agata Bielecka-Dabrowa, Jarosław Fabis, Dimitri P. Mikhailidis, Stephan von Haehling, Amirhossein Sahebkar, Jacek Rysz & Maciej Banach. (2018) Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. Trends in Pharmacological Sciences 39:4, pages 331-353.
Crossref
Crossref
Beatrice A. Golomb, Abril Verden, Alexis K. Messner, Hayley J. Koslik & Keith B. Hoffman. (2018) Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA’s Adverse Event Reporting System. Drug Safety 41:4, pages 403-413.
Crossref
Crossref
Ossama Elsaid, Beth Taylor, Amanda Zaleski, Gregory Panza & Paul D. Thompson. (2017) Rationale for investigating metformin as a protectant against statin-associated muscle symptoms. Journal of Clinical Lipidology 11:5, pages 1145-1151.
Crossref
Crossref
Hisakuni ObayashiNaoko KobayashiYoshikazu NezuTakashi YamotoMitsuyuki Shirai & Fumitoshi Asai. (2017) Plasma 2-hydroxyglutarate and hexanoylcarnitine levels are potential biomarkers for skeletal muscle toxicity in male Fischer 344 rats. The Journal of Toxicological Sciences 42:4, pages 385-396.
Crossref
Crossref
Danina M. Muntean, Paul D. Thompson, Alberico L. Catapano, Mariusz Stasiolek, Jaroslaw Fabis, Paul Muntner, Maria-Corina Serban & Maciej Banach. (2017) Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?. Drug Discovery Today 22:1, pages 85-96.
Crossref
Crossref
Edvard Ehler & Josef Zámečník. (2016) Toxic myopathies. Neurologie pro praxi 17:6, pages 386-390.
Crossref
Crossref
Jooyoung Kim, Joohyung Lee, Sojung Kim, Ho Young Ryu, Kwang Suk Cha & Dong Jun Sung. (2016) Exercise-induced rhabdomyolysis mechanisms and prevention: A literature review. Journal of Sport and Health Science 5:3, pages 324-333.
Crossref
Crossref
Gualberto Ruaño, Richard Seip, Andreas Windemuth, Alan H.B. Wu & Paul D. Thompson. (2016) Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia. Clinics in Laboratory Medicine 36:3, pages 473-491.
Crossref
Crossref
Negar Maghsoodi & Anthony S. Wierzbicki. (2016) Statin myopathy. Current Opinion in Cardiology 31:4, pages 417-425.
Crossref
Crossref
J. David Spence & George K. Dresser. (2016) Overcoming Challenges With Statin Therapy. Journal of the American Heart Association 5:1.
Crossref
Crossref
Paolo Magni, Chiara Macchi, Beatrice Morlotti, Cesare R. Sirtori & Massimiliano Ruscica. (2015) Risk identification and possible countermeasures for muscle adverse effects during statin therapy. European Journal of Internal Medicine 26:2, pages 82-88.
Crossref
Crossref
Patricio V Sepulveda, Ernest D Bush & Keith Baar. (2015) Pharmacology of manipulating lean body mass. Clinical and Experimental Pharmacology and Physiology 42:1, pages 1-13.
Crossref
Crossref
Nihal Simsek Ozek, I. Burak Bal, Yildirim Sara, Rustu Onur & Feride Severcan. (2014) Structural and functional characterization of simvastatin-induced myotoxicity in different skeletal muscles. Biochimica et Biophysica Acta (BBA) - General Subjects 1840:1, pages 406-415.
Crossref
Crossref
Ramesh C. Gupta, Michelle A. Lasher, Robin B. Doss & Dejan Milatovic. 2014. Biomarkers in Toxicology. Biomarkers in Toxicology
291
308
.
Jessica Fuhrmeister, Martha Tews, Andrea Kromer & Bernd Moosmann. (2012) Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells. Toxicology Letters 215:3, pages 219-227.
Crossref
Crossref
Christina Charles-Schoeman, Sogol S. Amjadi & Harold E. Paulus. (2012) Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey. Clinical Rheumatology 31:8, pages 1163-1168.
Crossref
Crossref
Ankur Gupta & Paul D. Thompson. (2011) The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 215:1, pages 23-29.
Crossref
Crossref
Kan CHIBA & Kaori MORIMOTO. (2011) Genetic Marker of Statin-induced Rhabdomyolysisスタチンによる横紋筋融解症の遺伝子マーカー. YAKUGAKU ZASSHI 131:2, pages 247-253.
Crossref
Crossref
Richard L. Seip, Jorge Duconge & Gualberto Ruaño. 2011. Pharmacogenomic Testing in Current Clinical Practice. Pharmacogenomic Testing in Current Clinical Practice
155
174
.
Stephanie L. Di StasiToran D. MacLeodJoshua D. WintersStuart A. Binder-Macleod. (2010) Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists. Physical Therapy 90:10, pages 1530-1542.
Crossref
Crossref
Marni J. Falk. (2010) Neurodevelopmental Manifestations of Mitochondrial Disease. Journal of Developmental & Behavioral Pediatrics 31:7, pages 610-621.
Crossref
Crossref
Guru M Krishnan & Paul D Thompson. (2010) The effects of statins on skeletal muscle strength and exercise performance. Current Opinion in Lipidology 21:4, pages 324-328.
Crossref
Crossref
Abhijit Ghatak, Osman Faheem & Paul D. Thompson. (2010) The genetics of statin-induced myopathy. Atherosclerosis 210:2, pages 337-343.
Crossref
Crossref
João Ettinger, Paulo Batista & Euler Ázaro. 2010. Morbid Obesity. Morbid Obesity.
. 2010. Morbid Obesity. Morbid Obesity.
Michael J. KnauerBradley L. UrquhartHenriette E. Meyer zu SchwabedissenUte I. SchwarzChristopher J. LemkeBrenda F. LeakeRichard B. KimRommel G. Tirona. (2010) Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins. Circulation Research 106:2, pages 297-306.
Crossref
Crossref
A. S. Wierzbicki. (2009) Storms, tea cups and the adverse effects of statins. International Journal of Clinical Practice 63:9, pages 1268-1270.
Crossref
Crossref
John D. Baxter & Paul Webb. (2009) Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nature Reviews Drug Discovery 8:4, pages 308-320.
Crossref
Crossref
Joanne E. Mallinson, Dumitru Constantin-Teodosiu, James Sidaway, F. Russell Westwood & Paul L. Greenhaff. (2009) Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. The Journal of Physiology 587:1, pages 219-230.
Crossref
Crossref